Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic's (MDT) TITAN 2 study will examine the safety and efficacy of the implantable TNM device in people with OAB.

Medtronic (MDT) Completes 1st Patient Implant of Implantable TNM

Medtronic is a shareholder-friendly company with a long history of dividend raises.

Why Medtronic Is Attractive While It's Still Down

Amcor Plc

Air Products and Chemicals

Franklin Resources

Colgate-Palmolive

Federal Realty Investment Trust

Kimberly-Clark

Leggett & Platt

McDonald's

Realty Income Corp

People's United Financial

V.F.

Walgreens

Exxon Mobil

"Dividend Aristocrats. in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing.

4 S&P 500 Aristocrats Are April's Top Dividend Dogs

TITAN 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the first patient implants in the TITAN 2 pivotal study that will evaluate the safety and efficacy of Medtronic's investigational implantable tibial neuromodulation (TNM) device in people with overactive bladder (OAB). The minimally invasive technology stimulates the posterior tibial nerve near the ankle, transmitting electrical impulses that regulate neural activity of the bladder.

Medtronic announces first patient implants of investigational implantable tibial neuromodulation therapy for bladder incontinence

Owens & Minor

Thermo Fisher Scientific

MedTech stocks like Owens & Minor (OMI), Thermo Fisher (TMO) and Medtronic (MDT) are prudent investment choices given their long-term growth potential with recent M&A deals.

3 Stocks to Focus on With MedTech M&A Scaling New Heights

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Medtronic (MDT) Up 3% Since Last Earnings Report: Can It Continue?

Let's see if Medtronic (MDT) stock is a good choice for value-oriented investors right now from multiple angles.

Is Medtronic (MDT) a Suitable Value Investor Stock Now?

Medtronic and Harris Poll survey finds 4 in 5 report chronic back or leg pain is worse or unimproved since the COVID-19 pandemic began DUBLIN , March 23, 2022 /PRNewswire/ -- A new survey commissioned by Medtronic plc (NYSE:MDT), a global leader in healthcare technology, and conducted by public opinion research firm The Harris Poll, finds nearly half (44%) of current chronic back and leg pain sufferers have experienced care delays during the COVID-19 pandemic, despite 87% reporting that their pain has not improved or even worsened since the pandemic began in March 2020. The national survey, "Painful Pandemic: How a Healthcare System Under Strain Impacts Chronic Pain Patients," of 810 U.S. adults who currently experience chronic back or leg pain finds far-reaching impacts of this debilitating condition on patient lifestyle, everyday activities, and mental state, further exacerbated by the pandemic's impact on stressed health systems and the ability of patients to seek timely care.

Medtronic survey finds pandemic creating far-reaching and negative impacts on those with chronic back or leg pain

Medtronic is one of the leading medical device companies in the world. The company's comprehensive product portfolio has fueled steady revenue and EBITDA growth.

Healthy Dividends: Bullish On Medtronic's Dividend Aristocrat Status

According to Medtronic (MDT), Touch Surgery Enterprise is the first AI-powered platform of its kind for the operating room (OR). It is compatible with Medtronic's Hugo robotic-assisted surgery (RAS) system.

Medtronic (MDT) Boosts Surgical Robotics Wing With New Deal

Caterpillar

Bank OZK

We find significant appeal in dividend stocks as relatively low interest rates for developed markets around the globe plague income-oriented investors, while sustained inflation threatens to erode our purchasing power, asserts Jason Clark, editor at The Prudent Speculator.

Dividend Aristocrats For "Prudent Speculators"

Intuitive Surgical

Both are two exceptional growth stocks -- but which is the better choice for investors now?

Better Buy: Intuitive Surgical vs. Medtronic

Que Dallara joins as EVP & President, Diabetes Mike Marinaro named President, Surgical Robotics Dr. Kweli Thompson named President, Cardiac Rhythm Management DUBLIN , March 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced leadership transitions for three of its Operating Units – Diabetes, Surgical Robotics, and Cardiac Rhythm Management – bringing in critical skills and capabilities and creating opportunities for internal talent. "The future of medical technology requires strong leadership in data science, artificial intelligence, and robotics, all of which make these three Operating Unit President roles some of the most important and dynamic leadership opportunities in our industry," said Geoff Martha, Medtronic chairman and chief executive officer.

Medtronic appoints new Operating Unit Presidents

Findings published in Gastroenterology show that AI technology assisted coloscopy improves the accuracy of polyp detection, which plays an important role in the prevention of colorectal cancer DUBLIN, March 16, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced final findings from a randomized, international, multi-center study that confirmed the effectiveness of the GI Genius™ intelligent endoscopy module, which uses AI as an aid in detecting colorectal polyps during colonoscopy, potentially helping to prevent colorectal cancer (CRC). The study, published on March 15 in Gastroenterology,  the official medical journal of the American Gastroenterological Association, found that the use of GI Genius in conjunction with colonoscopy significantly decreases the miss rate (2x) of colorectal polyps and adenomas compared to standard colonoscopy.

First U.S. trial using GI Genius™ intelligent endoscopy module shows 50% reduction in missed colorectal polyps with artificial intelligence (AI) technology versus standard colonoscopy

Investors are optimistic about Medtronic's (MDT) better-than-expected earnings and strong market share gains.

Here's Why You Should Hold on to Medtronic (MDT) Stock For Now

Bristol-Myers

Chubb

Illinois Tool Works

Philip Morris

SPDR S&P 500 ETF Trust

STAG Industrial

Stryker

Walmart

W. P. Carey

We provide a summary of upcoming ex-dividend dates in a quick reference table.

Upcoming Ex-Dividend Dates: March 16-31, 2022

Medtronic's (MDT) Touch Surgery Enterprise gives surgical teams a powerful new tool to enhance patient care by simplifying the process to capture and analyze surgical videos.

Medtronic (MDT) Inks Deal to Offer Touch Surgery Enterprise

Anheuser-Busch InBev

Medtronic and Anheuser-Busch will be good investments to hold as economic activity returns to normal.

2 Cheap Dividend Stocks Near Their 52-Week Lows

The first AI-powered video management and analytics platform for the OR, Touch Surgery Enterprise gives surgical teams easy access to procedural videos and insights DUBLIN, March 9, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has entered into a contract with Vizient, a leading healthcare performance improvement company in the U.S., to add Touch Surgery™ Enterprise to Vizient's offerings, which serve more than half the nation's healthcare providers. The first AI-powered surgical video management and analytics platform for the operating room (OR), Touch Surgery Enterprise significantly simplifies the process of recording, analyzing, and sharing surgical video — providing surgeons with a powerful new tool to improve performance and train others.1,† A fully integrated hardware and software system connected to the cloud, Touch Surgery Enterprise works easily with many laparoscopic and robotic scopes, enabling hospitals to take the first step to digitizing their OR while leveraging existing equipment.

Medtronic announces contract with Vizient for Touch Surgery™ Enterprise

Medtronic plc (MDT) Management Presents at 42nd Annual Cowen Health Care Conference Call Transcript

Ontario government's new comprehensive reimbursement program for CGM will enhance access to Medtronic's (MDT) integrated CGM technology for type 1 diabetes patients.

Medtronic (MDT) to Gain From New Reimbursement Program for CGM

Allscripts Healthcare Solutions

Syneos Health

MedTech stocks like Medtronic (MDT), Stryker (SYK), Allscripts Healthcare Solutions (MDRX) and Syneos Health (SYNH) are evolving rapidly in the field of AI-driven technologies.

4 Stocks in Spotlight With AI Making Inroads in MedTech

DUBLIN, March 4, 2022 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 3, 2022, approved the fiscal year 2022 fourth quarter cash dividend of $0.63 per ordinary share, representing an 8.6 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2021.

Medtronic announces cash dividend for fourth quarter of fiscal year 2022

In Respiratory Interventions, despite the year-over-year headwind, as ventilator sales continue to return to pre-pandemic levels, Medtronic (MDT) gains about 400 basis points of share.

Medtronic (MDT) Gains Market Share Despite COVID Headwinds

Curaleaf Holdings, Inc.

Even a small investment in these stocks can go a long way.

News for Medtronic Stock (MDT)